Get started
Author

Xiugao Yang

Observed names: X. Yang, Yang, Xiugao
Observed institution: CSPC Pharmaceutical Group
ORCID: 0000-0002-7101-7606
Observed ORCID: 0000-0002-7101-7606
OpenAlex ID: A5070850471
Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors
2022 · Xu Liang, Junli Xue, et al. · Frontiers in Oncology · 10
PDF
A multicenter, open-label, phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of JMT-101 in patients (pts) with advanced colorectal cancer (ACC).
2020 · Jian Li, Lin Shen, et al. · Journal of Clinical Oncology · 5
Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open‐label, multicenter, phase Ib trial
2024 · Jing Zuo, Wei Duan, et al. · 癌症：英文版 · 3
Efficacy and safety of duvelisib, a phosphoinositide 3 kinase (PI3K) δ and γ inhibitor, in Chinese patients (pts) with relapsed/refractory follicular lymphoma (R/R FL): A single-arm, open-label, multicenter, phase Ⅱ clinical trial.
2021 · Zhong Zheng, Yuhuan Gao, et al. · Journal of Clinical Oncology · 3
Safety, tolerability, and preliminary pharmacokinetic/pharmacodynamic profile of JMT103 in patients with bone metastases from solid tumors: A multicenter, open-label, dose-escalation, phase I clinical study.
2020 · Jin Li, Huiping Li, et al. · Journal of Clinical Oncology · 3
ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, for metastatic or unresectable osteosarcoma after standard chemotherapy: A multicenter, open-label, single-arm, phase 1 study.
2023 · Jingnan Shen, Wei Guo, et al. · Journal of Clinical Oncology · 2
Comparing becotarug plus osimertinib with a real-world osimertinib therapy cohort in platinum-refractory, advanced non–small cell lung cancer with EGFR exon 20 insertion.
2026 · Jian Fang, Wenfeng Fang, et al. · Journal of Clinical Oncology · 1
JMT101 in combination with irinotecan and SG001 versus regorafenib in patients with metastatic colorectal adenocarcinoma (mCRC): Results of a randomized, controlled, open-label, phase II study.
2025 · Jianmin Xu, Wentao Tang, et al. · Journal of Clinical Oncology · 1
Evaluation of the safety and efficacy of ALMB-0168, a novel monoclonal antibody activating Cx43 hemichannel, for osteosarcoma after standard therapy failure: A multicenter, open-label, single agent, phase 1/2 study (ACE study).
2025 · Jingnan Shen, Wei Guo, et al. · Journal of Clinical Oncology · 1
Abstract CT036: A first-in-human study result of a novel EGFR-targeted antibody drug conjugate (ADC) in patients with advanced nasopharyngeal carcinoma (NPC) (SYS6010-001-NPC)
2026 · Haiqiang Mai, Linquan Tang, et al. · Cancer Research
Durable disease control following treatment with ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, in femoral osteosarcoma with lung metastases after chemotherapy failure: a case report
2026 · Xianbiao Xie, Yiying Bian, et al. · Antibody Therapeutics
Dual EGFR Blockade With Becotatug And Osimertinib In Platinum-Pretreated Advanced Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations (BECOME): A Multicentre Phase 2 Trial
2026 · Shen Zhao, Yan Yu, et al. · SSRN Electronic Journal
929MO Becotatug (JMT101, Beco) combined with docetaxel (albumin-bound, HB1801) for the treatment of patients (pts) with locally advanced squamous cell non-small cell lung cancer (sqNSCLC): A randomized control phase II study (BATTLE study)
2025 · L. Zhang, W.F. Fang, et al. · Annals of Oncology
A phase II, randomized study of JMT101 in combination with irinotecan and SG001 versus regorafenib in patients with metastatic colorectal adenocarcinoma (mCRC).
2025 · Jianmin Xu, Wentao Tang, et al. · Journal of Clinical Oncology
Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer
2023 · Zhao, Shen, Zhuang, Wu, et al. · Figshare
Works count: 15
Citation count: 29
H-index: 3
I10-index: 1
Year
Topic
Type